Review Article

Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA

Table 1

Summary of the recommendations for each predisposition gene.

Predisposition genesCancer riskLifetime riskSurveillance

High-penetrance genes for breast and/or ovarian cancer

TP53Adrenocortical gland6–13% [25]Ultrasound of abdomen and pelvis: every 3–4 mos, birth to age 18 yrs [27]
Breast54% [25]Clinical breast examination: every 6–12 mos, age ≥ 20 yrs
Breast MRI screening with contrast (with or without mammogram): annually, age 20–75 yrs [27]
Central nervous system6–19% [25]Neurologic exam: annually, all ages
Brain MRI: annually [27]
Sarcomas5–22% [25]Whole-body MRI: annually, all ages
Ultrasound of abdomen and pelvis: annually, age ≥18 yrs [27]
Hematologic tumorsNAPeriodic blood test if increased risk for myelodysplastic syndrome or leukaemia [28]
Gastrointestinal systemNAUpper endoscopy and colonoscopy: every 2–5 yrs, age ≥25 yrs [27]
SkinNADermatologic exam: annually, age ≥18 yrs [27]

PTENBreast85% [5]Clinical breast examination: every 6 mos, age ≥ 25 yrs
Mammogram and breast MRI with contrast: annually, age 30–75 yrs [6]
Thyroid35% [36]Ultrasound of thyroid: annually, all ages [6]
Endometrium28% [36]Endometrial biopsy: every 1–2 yrs [6]
Colon and rectum9% [36]Colonoscopy: every 5 yrs, age ≥ 35 yrs [6]
Kidney30% [36]CT or MRI of abdomen: every 1–2 yrs, age ≥ 40 yrs [6]
Melanoma5% [38]Dermatologic exam: annually, age ≥18 yrs [38]

CDH1Stomach56–83% [8]Upper endoscopy: every 6–12 mos, age ≥ 18 yrs [59]
Breast52% [8]Mammogram and breast MRI with contrast: annually, age ≥ 30 yrs [6]

STK11Colon and rectum39% [9]Colonoscopy: every 2–3 yrs, age ≥ 18 yrs [61]
Stomach29% [9]Upper endoscopy: every 2–3 yrs, age ≥ 18 yrs [61]
Small bowel13% [9]Capsule endoscopy: every 2–3 yrs, age ≥ 18 yrs [61]
Pancreas11–36% [9]MR cholangiopancreatography with contrast or endoscopic ultrasound: every 1–2 yrs, age ≥ 30 yrs [62]
Breast32–54% [9]Clinical breast examination: every 6 mos, age ≥ 20 yrs
Mammogram and breast MRI with contrast: annually, age ≥ 25 yrs [6]
Ovary, cervix, and uterus9–21% [9]Transvaginal ultrasound, serum CA 125, pelvic exam with pap smear: annually, age ≥ 18 yrs [6]
Testis9% [9]Testicular exam: annually, until 18 yrs [62]
Lung7–17% [9]Not recommended
Low-/moderate-penetrance genes for breast and/or ovarian cancer

PALB2Breast35% [69]Mammogram and breast MRI with contrast: annually, age ≥ 30 yrs [6]
Ovary, pancreasNANot recommended

CHEK2Breast28–37% [13, 75]Mammogram and breast MRI with contrast: annually, age ≥ 40 yrs [6]
ColonNAColonoscopy: every 5 yrs, age ≥ 40 yrs [6]
Prostate, kidney, bladder, and thyroidNANot recommended

NBN (675del5)BreastUp to 30% [77]Breast MRI with contrast: annually, age ≥ 40 yrs [6]
Ovary and prostateNANot recommended

MLH1, MSH2, MSH6, PMS2, EPCAMColon and rectum48–57% [43]Colonoscopy: every 1-2 yrs, age ≥ 20–25 yrs [6]
Endometrium43–57% [43]Not recommended
OvaryUp to 24% [43]Not recommended
Stomach, small bowel4–13% [43]Upper endoscopy: every 3–5 yrs, age ≥ 40 yrs if relevant family history or mutation in MLH1, MSH2 or EPCAM [45, 51]
Hepatobiliary tractUp to 4% [43]In research protocol [6]
Urinary tractUp to 25% [43]Urinalysis: annually, age ≥ 30–35 yrs if relevant family history or MSH2 mutation [6]
Brain1–4% [43]Physical and neurologic examination: annually, age ≥ 25–30 yrs [6]
Breast (MSH2, MLH1, PMS2, or MSH6)11–18% [5355]Not recommended
ProstateNANot recommended

ATMBreast33% [12]Mammogram with consideration of breast MRI with contrast: annually, age ≥ 40 yrs [6]
Ovary, prostate, and pancreasNANot recommended
BRIP1, RAD51C, RAD51DOvaryUp to 10% [15]Not recommended

NF1Nervous system8–16% [64]Physical and eye examination: annually, every age [63, 64]
Breast17% [64]Mammogram and breast MRI with contrast: annually, age 30–50 yrs [65]
BARD1BreastNANot recommended

NA = not available, Risk-reducing surgery can be considered based on type of mutation and family history.